WO2003018799A3 - Modulators of bone homeostasis identified in a high-throughput screen - Google Patents

Modulators of bone homeostasis identified in a high-throughput screen Download PDF

Info

Publication number
WO2003018799A3
WO2003018799A3 PCT/EP2002/009530 EP0209530W WO03018799A3 WO 2003018799 A3 WO2003018799 A3 WO 2003018799A3 EP 0209530 W EP0209530 W EP 0209530W WO 03018799 A3 WO03018799 A3 WO 03018799A3
Authority
WO
WIPO (PCT)
Prior art keywords
relates
present
throughput screen
methods
modulators
Prior art date
Application number
PCT/EP2002/009530
Other languages
French (fr)
Other versions
WO2003018799A2 (en
Inventor
Hubertus Johannes Mat Klaassen
Peter Herwig Maria Tomme
Es Helmuth Hendrikus Gerar Van
Rompaey Luc Van
Original Assignee
Galapagos Genomics Nv
Hubertus Johannes Mat Klaassen
Peter Herwig Maria Tomme
Es Helmuth Hendrikus Gerar Van
Rompaey Luc Van
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Genomics Nv, Hubertus Johannes Mat Klaassen, Peter Herwig Maria Tomme, Es Helmuth Hendrikus Gerar Van, Rompaey Luc Van filed Critical Galapagos Genomics Nv
Priority to CA002457879A priority Critical patent/CA2457879A1/en
Priority to JP2003523648A priority patent/JP2005503792A/en
Priority to EP02796279A priority patent/EP1438402A2/en
Publication of WO2003018799A2 publication Critical patent/WO2003018799A2/en
Publication of WO2003018799A3 publication Critical patent/WO2003018799A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

The invention relates to the field of molecular genetics and medicine. In particular, the present invention relates to the field of functional genomics, i.e., to a method for the identification of genes that function in regulating bone homeostasis, such as the induction of osteogenesis. In particular, the present invention relates to polynucleotides and the encoded polypeptides that are identified in a high-throughput screen designed to detect modulation of bone alkaline phosphatase activity. Moreover, the present invention relates to vectors, host cells, antibodies and diagnostic methods for detecting diseases involving the discovered polynucleotides, and therapeutic methods for treating such diseases. The invention further relates to methods and means for drug compound screens designed to develop new therapeutic strategies.
PCT/EP2002/009530 2001-08-22 2002-08-22 Modulators of bone homeostasis identified in a high-throughput screen WO2003018799A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002457879A CA2457879A1 (en) 2001-08-22 2002-08-22 Modulators of bone homeostasis identified in a high-throughput screen
JP2003523648A JP2005503792A (en) 2001-08-22 2002-08-22 Bone homeostasis modulator identified in high-throughput screening
EP02796279A EP1438402A2 (en) 2001-08-22 2002-08-22 Modulators of bone homeostasis identified in a high-throughput screen

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US31405601P 2001-08-22 2001-08-22
US60/314,056 2001-08-22
EP01870181 2001-08-22
EP01870181.3 2001-08-22
US35693502P 2002-02-14 2002-02-14
US60/356,935 2002-02-14

Publications (2)

Publication Number Publication Date
WO2003018799A2 WO2003018799A2 (en) 2003-03-06
WO2003018799A3 true WO2003018799A3 (en) 2004-03-11

Family

ID=56290324

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/009530 WO2003018799A2 (en) 2001-08-22 2002-08-22 Modulators of bone homeostasis identified in a high-throughput screen

Country Status (4)

Country Link
EP (1) EP1438402A2 (en)
JP (1) JP2005503792A (en)
CA (1) CA2457879A1 (en)
WO (1) WO2003018799A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003300239A1 (en) 2003-12-29 2005-07-21 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
WO2005124343A2 (en) * 2004-06-16 2005-12-29 Galapagos N.V. Methods for modulating bone tissue formation, orthogenic agents and pharmaceutical compositions
WO2005124342A2 (en) 2004-06-21 2005-12-29 Galapagos N.V. Methods and means for treatment of osteoarthritis
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
AU2009313560B2 (en) 2008-11-07 2016-04-14 Fabrus Llc Combinatorial antibody libraries and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005775A1 (en) * 1996-08-01 1998-02-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Gene involved in cadasil, method of diagnosis and therapeutic application
WO1998039446A2 (en) * 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 70 human secreted proteins
WO1998045434A1 (en) * 1997-04-04 1998-10-15 Millennium Biotherapeutics, Inc. Novel human delta3 compositions and therapeutic and diagnostic uses therefor
WO1999064582A2 (en) * 1998-06-12 1999-12-16 Introgene B.V. High-throughput screening of gene function using libraries for functional genomics applications
WO2000006726A2 (en) * 1998-07-27 2000-02-10 Amgen Inc. Delta-related polypeptides
EP1004669A1 (en) * 1997-05-14 2000-05-31 Asahi Kasei Kogyo Kabushiki Kaisha Novel differentiation inhibitor

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005775A1 (en) * 1996-08-01 1998-02-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Gene involved in cadasil, method of diagnosis and therapeutic application
WO1998039446A2 (en) * 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 70 human secreted proteins
WO1998045434A1 (en) * 1997-04-04 1998-10-15 Millennium Biotherapeutics, Inc. Novel human delta3 compositions and therapeutic and diagnostic uses therefor
EP1004669A1 (en) * 1997-05-14 2000-05-31 Asahi Kasei Kogyo Kabushiki Kaisha Novel differentiation inhibitor
WO1999064582A2 (en) * 1998-06-12 1999-12-16 Introgene B.V. High-throughput screening of gene function using libraries for functional genomics applications
WO2000006726A2 (en) * 1998-07-27 2000-02-10 Amgen Inc. Delta-related polypeptides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DALLAS D.J. ET AL: "Stimulation of osteoblast differentiation and bone formation in vitro and in vivo by Notch receptor-ligand interactions", JOURNAL OF BONE AND MINERAL RESEARCH, vol. 14, no. SUPPL 1, September 1999 (1999-09-01), pages S172, XP002237112, ISSN: 0884-0431 *
LOU J. ET AL.: "Gene therapy: adenovirus-mediated human bone morphogenetic protein-2 gene transfer induces mesenchymal progenitor cell proliferation and differentiation in vitro and bone formation in vivo", JOURNAL OF ORTHOPAEDIC RESEARCH, vol. 17, no. 1, January 1999 (1999-01-01), pages 43 - 50, XP002194122 *
SHUTTER J.R. ET AL.: "Dll4, a novel Notch ligand expressed in arterial endothelium", GENES & DEVELOPMENT, vol. 14, no. 11, 1 June 2000 (2000-06-01), pages 1313 - 1318, XP002237111 *
TEZUKA K. ET AL.: "Actions of Notch on osteoblastic and chondrogenic cell differentiation", JOURNAL OF BONE AND MINERAL RESEARCH, vol. 15, no. Suppl.1, September 2000 (2000-09-01), pages S217, XP008015904 *

Also Published As

Publication number Publication date
CA2457879A1 (en) 2003-03-06
WO2003018799A2 (en) 2003-03-06
JP2005503792A (en) 2005-02-10
EP1438402A2 (en) 2004-07-21

Similar Documents

Publication Publication Date Title
WO2002095051A3 (en) Mage-a3 peptides presented by hla class ii molecules
WO2000055318A3 (en) Abc1 polypeptide and methods and reagents for modulating cholesterol levels
WO2004047863A3 (en) Genetic products differentially expressed in tumors and the use thereof
WO1999053061A3 (en) Tumor associated nucleic acids and uses therefor
WO2001068859A3 (en) Il-17 receptor like molecules and uses thereof
WO2003076631A3 (en) Genetic products differentially expressed in tumors and use thereof
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
WO2003018799A3 (en) Modulators of bone homeostasis identified in a high-throughput screen
WO2005026205A3 (en) Genetic products which are differentially expressed in tumours and use thereof
WO2001009183A3 (en) Polymorphisms in the human mdr-1 gene and applications thereof
WO2000022122A3 (en) Genes, proteins and biallelic markers related to central nervous system disease
WO2004051269A3 (en) Ciz1 replication protein
IL207012A (en) Pharmaceutical composition comprising sgp28 and a vaccine composition for the treatment of a cancer expressing sgp28
WO2001064876A3 (en) Human schizophrenia gene
WO2001059120A3 (en) Il-17 like molecules and uses thereof
WO2003087408A3 (en) Schizophrenia associated genes
WO2003031586A3 (en) Acrp30-like polynucleotides, polypeptides, and antibodies
ATE496129T1 (en) SSX-2 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
WO2004058949A3 (en) Wnt-1 inhibitory factor-1 (wif-1) molecules and uses thereof
WO2002018536A3 (en) Truncated bard1 protein, and its diagnostic and therapeutic uses
AU6039400A (en) Mutated nurr1 gene
WO2002097110A3 (en) TUMOR ENDOTHELIAL MARKER 7α MOLECULES AND USES THEREOF
WO2003027235A3 (en) Afap sequences, polypeptides, antibodies and methods
WO2003025198A3 (en) Regulatory single nucleotide polymorphisms and methods therefor
AU2001244151A1 (en) Peptide and nucleic acid coding therefor for the detection, diagnosis and therapy of diseases of the nervous system

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2457879

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003523648

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002333718

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002796279

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002796279

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002796279

Country of ref document: EP